Two Sigma Advisers LP raised its position in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 12.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 428,700 shares of the company’s stock after acquiring an additional 48,800 shares during the period. Two Sigma Advisers LP owned approximately 1.20% of Medpace worth $22,691,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently bought and sold shares of MEDP. LS Investment Advisors LLC purchased a new stake in Medpace in the fourth quarter worth about $46,000. State of Alaska Department of Revenue purchased a new stake in shares of Medpace during the fourth quarter valued at about $92,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Medpace during the fourth quarter valued at about $119,000. We Are One Seven LLC purchased a new stake in shares of Medpace during the fourth quarter valued at about $130,000. Finally, Great West Life Assurance Co. Can lifted its position in shares of Medpace by 270.1% during the third quarter. Great West Life Assurance Co. Can now owns 3,331 shares of the company’s stock valued at $200,000 after buying an additional 2,431 shares during the last quarter. Institutional investors and hedge funds own 83.17% of the company’s stock.
In other news, CEO August J. Troendle sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $61.00, for a total transaction of $36,600.00. Following the sale, the chief executive officer now owns 603,702 shares of the company’s stock, valued at approximately $36,825,822. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 8,760 shares of the firm’s stock in a transaction that occurred on Thursday, January 17th. The stock was sold at an average price of $61.17, for a total transaction of $535,849.20. Following the sale, the chief executive officer now directly owns 603,702 shares in the company, valued at approximately $36,928,451.34. The disclosure for this sale can be found here. In the last quarter, insiders sold 705,800 shares of company stock worth $44,657,456. 29.50% of the stock is owned by corporate insiders.
Shares of MEDP traded up $0.12 during mid-day trading on Monday, hitting $58.88. 266,800 shares of the company traded hands, compared to its average volume of 673,758. Medpace Holdings Inc has a 1-year low of $35.00 and a 1-year high of $71.66. The company has a quick ratio of 0.69, a current ratio of 0.69 and a debt-to-equity ratio of 0.18. The company has a market cap of $2.11 billion, a P/E ratio of 22.73, a price-to-earnings-growth ratio of 1.91 and a beta of 1.62.
Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 25th. The company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.07. Medpace had a net margin of 11.27% and a return on equity of 17.66%. The company had revenue of $192.12 million for the quarter, compared to the consensus estimate of $184.66 million. During the same quarter in the prior year, the company earned $0.39 EPS. Medpace’s quarterly revenue was up 70.5% on a year-over-year basis. On average, research analysts anticipate that Medpace Holdings Inc will post 2.64 EPS for the current fiscal year.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Further Reading: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.